Colorcon launches Opadry Enteric for use with hydro-alcoholic media
A fully formulated one-step system providing simple preparation and ease-of-use for film coating.
Colorcon has announced another innovative addition to their portfolio of delayed-release coatings for pharmaceutical applications. This latest development incorporates hydroxypropyl methylcellulose phthalate (hypromellose phthalate or HPMC-P) as the functional polymer in an advanced one-step film coating system offering enteric performance for hydro-alcoholic applications.
Opadry Enteric is a fully formulated one-step system providing simple preparation and ease-of-use for film coating; resulting in reduced inventory and QC testing compared to multi-component coating systems. This new system provides a further option to the company's existing Opadry delayed-release product line based on acrylic and PVAP polymers.
Dr Daniel To, Product Development Manager, explains: “As a fully formulated system Opadry Enteric, based on HPMC-P, brings not only convenience but also reduces potential errors of raw material handling and application during manufacturing. Our application data, generated during the product’s development, clearly demonstrates consistent and stable enteric performance for a number of APIs.”
Greater efficiency for solvent coating
Kelly Boyer, General Manager, Film Coatings at Colorcon notes: “Opadry Enteric is formulated for use with hydro-alcoholic media and can be color matched to meet the marketing and brand needs of pharmaceutical products. As a one-step hydro-alcoholic coating, preparation time is significantly reduced and, by using Colorcon’s expertise in color matching, batch-to-batch variability is eliminated.”
This new fully formulated delayed release coating, providing enteric protection represents Colorcon’s continued innovation and leadership in developing formulated film coating systems that bring enhanced functionality along with improved convenience for pharmaceutical formulators.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance